CytoDyn to Present Prolonged Survival Data on Lero
Post# of 158771
(Total Views: 697)
Posted On: 11/24/2025 8:31:35 AM
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Download as PDFNovember 24, 2025 8:30am EST
Company to deliver a poster presentation on clinical data demonstrating sustained remission
following immune checkpoint inhibitor therapy with or after leronlimab treatment
in patients with metastatic or locally advanced triple-negative breast cancer
VANCOUVER, Washington, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), announced today that Dr. Milana V. Dolezal, Clinical Associate Professor, Medicine Oncology at Stanford University School of Medicine, will present a poster at the prestigious San Antonio Breast Cancer Symposium (SABCS), being held December 9-12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Currently, mTNBC is associated with a poor prognosis. The efficacy of immune checkpoint inhibitors (ICIs) is reduced in patients with mTNBC who have low levels of PD-L1[1]. A recent review of CytoDyn’s prior oncology trials suggests that treatment with leronlimab was associated with an increase in levels of PD-L1, and that when combined with an ICI or preceded by treatment with an ICI, it may improve survival in patients with mTNBC[2].
“Our strategy to use leronlimab in a combined approach with ICIs continues to demonstrate great promise,” said Jacob Lalezari, M.D., CEO of CytoDyn. “At SABCS 2025, we look forward to sharing details of a group of patients with mTNBC who were treated with leronlimab and different commercially available PD-L1/PD-1 immune checkpoint inhibitors who continue to demonstrate sustained long-term remission, including 3 individuals with no current evidence of disease.”
Details of the poster presentation are as follows:
Title: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab-induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer
Presenter: Dr. Milana V. Dolezal, MD, MSci, Clinical Associate Professor, Medicine Oncology at Stanford University School of Medicine
Poster ID: PS5-02-30
Date/Time: December 12, 2025, 12:30 PM–2:00 PM CST
Location: Exhibit Hall
A copy of the presentations will be made available on CytoDyn’s website under the Publications & Posters section after it is presented at the symposium.
Download as PDFNovember 24, 2025 8:30am EST
Company to deliver a poster presentation on clinical data demonstrating sustained remission
following immune checkpoint inhibitor therapy with or after leronlimab treatment
in patients with metastatic or locally advanced triple-negative breast cancer
VANCOUVER, Washington, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), announced today that Dr. Milana V. Dolezal, Clinical Associate Professor, Medicine Oncology at Stanford University School of Medicine, will present a poster at the prestigious San Antonio Breast Cancer Symposium (SABCS), being held December 9-12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Currently, mTNBC is associated with a poor prognosis. The efficacy of immune checkpoint inhibitors (ICIs) is reduced in patients with mTNBC who have low levels of PD-L1[1]. A recent review of CytoDyn’s prior oncology trials suggests that treatment with leronlimab was associated with an increase in levels of PD-L1, and that when combined with an ICI or preceded by treatment with an ICI, it may improve survival in patients with mTNBC[2].
“Our strategy to use leronlimab in a combined approach with ICIs continues to demonstrate great promise,” said Jacob Lalezari, M.D., CEO of CytoDyn. “At SABCS 2025, we look forward to sharing details of a group of patients with mTNBC who were treated with leronlimab and different commercially available PD-L1/PD-1 immune checkpoint inhibitors who continue to demonstrate sustained long-term remission, including 3 individuals with no current evidence of disease.”
Details of the poster presentation are as follows:
Title: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab-induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer
Presenter: Dr. Milana V. Dolezal, MD, MSci, Clinical Associate Professor, Medicine Oncology at Stanford University School of Medicine
Poster ID: PS5-02-30
Date/Time: December 12, 2025, 12:30 PM–2:00 PM CST
Location: Exhibit Hall
A copy of the presentations will be made available on CytoDyn’s website under the Publications & Posters section after it is presented at the symposium.
(13)
(0)